Medicare launched a GLP-1 Bridge Program in July 2026, giving qualifying seniors access to select weight loss medications at a dramatically reduced cost.
The program runs through December 31, 2027, and caps monthly costs at $50 for eligible beneficiaries who meet specific health and insurance criteria.
Before this program, seniors on Medicare who wanted GLP-1 medications for weight loss had no choice but to pay out of pocket, which can run into hundreds of dollars monthly.
The surge in demand for GLP-1 drugs over recent years has outpaced insurance coverage options, leaving many patients without affordable access to these treatments.
Three drugs are currently covered under the program: Foundayo in tablet form, Wegovy in injection or tablet form, and Zepbound via KwikPen only.
To qualify, beneficiaries must hold a Medicare Part D plan or a Medicare Advantage plan that includes prescription drug coverage, and must not already be eligible to receive a GLP-1 through their existing drug plan.
Seniors with type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease are excluded from the program under the current eligibility rules.
Qualifying patients must be at least 18 years old and meet specific body mass index thresholds tied to related health conditions such as heart failure, high blood pressure, chronic kidney disease, prediabetes, or a history of heart attack or stroke.
Doctors are required to submit a prior authorization form to Medicare on behalf of patients before any prescriptions can be filled through the program.
Because the program operates separately from a beneficiary’s Part D plan, the $50 monthly co-pays do not count toward the Part D annual out-of-pocket maximum.
That distinction is worth noting for seniors carefully managing their total yearly healthcare spending and planning around predictable retirement expenses.
Weight loss achieved through GLP-1 medications may also reduce the risk of developing other costly chronic conditions down the line, potentially stretching retirement savings further.
Seniors interested in the program are encouraged to speak with their doctor first to determine eligibility, and to contact the Centers for Medicare and Medicaid Services with any questions about program details.
The GLP-1 Bridge Program represents a meaningful shift in how Medicare approaches obesity treatment, with broader implications for senior health outcomes and long-term healthcare costs.
